Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.

Jesús F Bermejo-Martin[1,2,3]*, Milagros González-Rivera[4,5] *, Raquel Almansa[1,2,3]*, Dariela Micheloud[6]*, Ana P. Tedim[1,2]*, Marta Domínguez-Gil[7]*, Salvador Resino[8]*, Marta Martín-Fernández[1,2], Pablo Ryan Murua[9], Felipe Pérez-García[10], Luis Tamayo[1,11], Raúl Lopez-Izquierdo[12], Elena Bustamante[13], César Aldecoa[1,14,15], José Manuel Gómez[16], Jesús Rico-Feijoo[1,15], Antonio Orduña[17], Raúl Méndez[18], Isabel Fernández Natal[19], Gregoria Megías[20], Montserrat González-Estecha[4,5], Demetrio Carriedo[21], Cristina Doncel [1,2,3], Noelia Jorge [1,2,3], Alicia Ortega[1,2,3], Amanda de la Fuente[1,2,3], Félix del Campo[22], José Antonio Fernández-Ratero[23],Wysali Trapiello [24], Paula González-Jiménez[18], Guadalupe Ruiz[24], Alyson A. Kelvin[25,26], Ali Toloue Ostadgavahi[25,26], Ruth Oneizat[7], Luz María Ruiz[7], Iria Miguéns[6], Esther Gargallo[6], Ioana Muñoz[6], Sara Pelegrin[15], Silvia Martín[1,15], Pablo García Olivares[16], Jamil Antonio Cedeño[16], Tomás Ruiz Albi[22], Carolina Puertas[4], Jose Ángel Berezo[1,11], Gloria Renedo[13], Rubén Herrán[1,11], Juan Bustamante-Munguira[27], Pedro Enríquez[11], Ramón Cicuendez[13], Jesús Blanco[11], Jesica Abadia[28], Julia Gómez Barquero[28], Nuria Mamolar[13], Natalia Blanca-López[9], Luis Jorge Valdivia[21], Belén Fernández Caso[19], María Ángeles Mantecón[20], Anna Motos[3,29], Laia Fernandez-Barat [3,29], Ricard Ferrer[3,30], Ferrán Barbé[3,31], Antoni Torres[3,29 Δ], Rosario Menéndez[3,18 Δ], José María Eiros[7 Δ] , David J Kelvin[Δ 25,26.]

* These authors contributed equally

[Δ] These authors contributed equally

1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca, Spain

2. Hospital Universitario Río Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.

3. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain

4. Department of Laboratory Medicine, Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.

5. Department of Medicine, Faculty of Medicine, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.

6. Emergency Department, Hospital General Universitario Gregorio Marañón, Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.

7. Microbiology Service, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain

8. Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. de Pozuelo, 28, 28222 Majadahonda, Spain

9. Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain

10. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Carr. de Alcalá, s/n, 28805, Madrid, Spain

11. Intensive Care Unit, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.

12. Emergency Department, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.

13. Intensive Care Unit, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal, 3, 47003 Valladolid, Spain

14. Department of Anesthesiology, Facultad de Medicina de Valladolid, Av. Ramón y Cajal, 7, 47005 Valladolid, Spain.

15. Anesthesiology and Reanimation Service, Hospital Universitario Rio Hortega, Calle Dulzaina, 2, 47012 Valladolid, Spain.

16. Intensive Care Unit. Hospital General Universitario Gregorio Marañón. Calle del Dr. Esquerdo, 46, 28007 Madrid, Spain.

17. Microbiology Service, Hospital Clinico Universitario de Valladolid, Av. Ramón y Cajal, 3, 47003 Valladolid, Spain.

18. Pulmonology Service, Hospital Universitario y Politécnico de La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia Spain

19. Clinical Microbiology Department. Complejo Asistencial Universitario de León. Calle Altos de nava, s/n, 24001 León, Spain.

20. Microbiology Service, Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006 Burgos, Spain

21. Intensive Care Unit. Complejo Asistencial Universitario de León. Calle Altos de nava, s/n, 24001 León, Spain.

22. Pneumology Service, Hospital Universitario Río Hortega / Biomedical Engineering Group, Universidad de Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain.

23. Intensive Care Unit. Hospital Universitario de Burgos, Av. Islas Baleares, 3, 09006 Burgos, Spain.

24. Clinical Analysis Service. Hospital Clínico Universitario de Valladolid, Av. Ramón y Cajal, 3, 47003 Valladolid, Spain

25. Department of Microbiology and Immunology, Faculty of Medicine, Canadian Center for Vaccinology CCfV, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada

26. Laboratory of Immunity, Shantou University Medical College, 22 Xinling Rd, Jinping, Shantou, Guangdong, China.

27. Department of Cardiovascular Surgery, Hospital Clínico Universitario de Valladolid. Av. Ramón y Cajal, 3, 47003 Valladolid, Spain

28. Infectious diseases clinic, Internal Medicine Department, Hospital Universitario Río Hortega, Valladolid, Calle Dulzaina, 2, 47012 Valladolid, Spain

29. Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, Institut D investigacions August Pi I Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036 Barcelona, Spain.

30. Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research Group, Vall d'Hebron Institut de Recerca, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain.

31. Respiratory Department, Institut Ricerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain.

Corresponding author: David J Kelvin Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada. E-mail address: dkelvin@jidc.org.

Abstract

Background: COVID-19 can course with respiratory and extrapulmonary disease. SARS-CoV-2 RNA is detected in respiratory samples but also in blood, stool and urine. Severe COVID-19 is characterised by a dysregulated host response to this virus. We studied whether viral RNAemia or viral RNA load in plasma are associated to severe COVID-19 and also to this dysregulated response.

Methods: 250 patients with COVID-19 were recruited (50 outpatients, 100 hospitalised ward patients, and 100 critically ill). Viral RNA detection and quantification in plasma was performed using droplet digital PCR, targeting the N1 and N2 regions of the SARS-CoV-2 nucleoprotein gene. The association between SARS-CoV-2 RNAemia and viral RNA load in plasma with severity was evaluated by multivariate logistic regression. Correlations between viral RNA load and biomarkers evidencing dysregulation of host response were evaluated by calculating the Spearman correlation coefficients.

Results: the frequency of viral RNAemia was higher in the critically ill patients (78%) compared to ward patients (27%) and outpatients (2%) (p<0.001). Critical patients had higher viral RNA loads in plasma than non-critically ill patients, with non survivors showing the highest values. When outpatients and ward patients were compared, viral RNAemia did not show significant associations in the multivariate analysis. In contrast, when ward patients were compared with ICU patients, both viral RNAemia and viral RNA load in plasma were associated with critical illness (OR [CI 95%], p): RNAemia (3.92 [1.183 - 12.968], 0.025), viral RNA load (N1) (1.962 [1.244 - 3.096], 0.004); viral RNA load (N2) (2.229 [1.382 - 3.595], 0.001). Viral RNA load in plasma correlated with higher levels of chemokines (CXCL10, CCL2), biomarkers indicative of a systemic inflammatory response (IL-6, CRP, Ferritin), activation of NK cells (IL-15), endothelial dysfunction (VCAM-1, angiopoietin-2, ICAM-1), coagulation activation (D-Dimer and INR), tissue

damage (LDH, GPT), neutrophil response (neutrophils counts, myeloperoxidase, GM-CSF) and immunodepression (PD-L1, IL-10, lymphopenia and monocytopenia).

Conclusions: SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19. Viral RNA load in plasma correlates with key signatures of dysregulated host responses, suggesting a major role of uncontrolled viral replication in the pathogenesis of this disease.

Key words: SARS-CoV-2, cytokine, sepsis, COVID-19, plasma, RNAemia, viral RNA load, ICU

Background

With well over 43 million cases and 1.56212 deaths globally, Coronavirus disease 2019 (COVID-19) has become the top economic and health priority worldwide [1]. Among hospitalized patients, around 10–20% are admitted to the intensive care unit (ICU), 3–10% require intubation and 2–5% die [2]. SARS-CoV-2 RNA is commonly detected in nasopharyngeal swabs; however viral RNA can be found in sputum, lung samples, peripheral blood, serum, stool samples, and to a limited extent urine [3] [4] [5] [6]. While the lungs are most often affected, severe COVID-19 also induce inflammatory cell infiltration, haemorrhage, and degeneration or necrosis in extra-pulmonary organs (spleen, lymph nodes, kidney, liver, central nervous system) [7] [8]. Patients with severe COVID-19 show signatures of dysregulated response to infection, with immunological alterations involving moderate elevation of some cytokines and chemokines such as IL-6, IL-10 or CXCL10, deep lymphopenia with neutrophilia, systemic inflammation (elevation of C Reactive Protein, ferritin), endothelial dysfunction, coagulation hyper-activation (D-dimers) and tissue damage (LDH) [9] [10] [11] [12] [13] [14].

Our hypothesis is that systemic distribution of the virus or viral components could be associated to the severity of COVID-19, and, in turn to a number of parameters indicating the presence of a dysregulated response to the infection.

While the SARS-CoV-2 virus has been reported to be difficult to culture from blood [4], PCR based methods are able to detect and quantify the presence of genomic material of the virus in serum or plasma, representing an useful approach to evaluate the impact of the extrapulmonary dissemination of viral material on disease severity and also on the host response to the infection [5] [15]. An excellent approach for achieving absolute quantification of viral RNA load is droplet digital PCR (ddPCR). ddPCR is a next-

generation PCR method, which offers absolute quantification with no need of standard curve and greater precision and reproducibility than currently available qRT-PCR methods, as revised elsewhere [16].

We employed here ddPCR to detect and quantify viral RNA in plasma from COVID-19 patients discharged from the emergency room with mild severity, patients admitted to the ward with moderate severity, and critically ill patients. Our objectives in this study were: 1) to evaluate if there is an association between SARS-CoV-2 RNAemia and viral RNA load with moderate disease; 2) to evaluate if there is an association between SARS-CoV-2 RNAemia and viral RNA load with critical illness; 3) to evaluate the correlations between SARS-CoV-2 RNA load in plasma and parameters of dysregulated host responses against SARS-CoV-2.

Methods

Study design: 250 adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 performed at participating hospitals were recruited during the first pandemic wave in Spain from March 16th to the 15th of April 2020. The patients recruited were of three different categories. The first corresponded to patients examined at an emergency room and discharged within the first 24 hours (outpatients group, n=50). The second group were patients hospitalized to pneumology, infectious diseases or internal medicine wards (wards group, n=100). Patients who required critical care or died during hospitalization were excluded from this group, in order to have a group of clear moderate severity. The third group corresponded to patients admitted to the ICU (n=100). Patient`s recruited by participating hospital are detailed in the additional file 1. 20 healthy blood donors were included as controls. These controls were recruited during the pandemics, in parallel to the SARS-CoV-2 infected patients, and were negative for SARS-CoV-2 IgG. This study was registered at Clinicaltrials.gov with the identification NCT04457505.

Blood samples: Plasma from blood collected in EDTA tubes samples was obtained from the three groups of patients in the first 24 hours following admission to the emergency room, to the ward, or to the ICU, at a median collection day since disease onset of 7, 8 and 10 respectively, and also. from 20 blood donors (10 men and 10 women).

Biomarker profiling: a panel of biomarkers was profiled by using the Ella-SimplePlex™ immunoassay (San Jose, California, U.S.A), informing of the following biological functions potentially altered in severe COVID-19, based in the available evidence on COVID-19 physiopathology [13] [17] and also in our previous experience on emerging infections and sepsis [18] [19] [20] [21]: neutrophil degranulation: Lipocalin-2/NGAL, myeloperoxidase; endothelial dysfunction: ICAM-1, VCAM-1/CD106, Angiopoietin 2; T

209 cell survival and function: IL-7, Granzyme B; immunosuppression: IL-1ra, B7-H1/PD-L1,
210 IL-10; chemotaxis: CXCL10/IP10, CCL2; Th1 response: Interleukin 1 beta, IFN-γ, IL-
211 12p70, IL-15, TNF-α, IL-2; Th2 response: IL-4, IL-10; Th17 response: IL-6, IL-17A;
212 granulocyte mobilization / activation: G-CSF, GM-CSF; coagulation activation: D-Dimer;
213 acute phase reactants: Ferritin (C Reactive protein and LDH were profiled in each
214 participant hospital by their central laboratories).

215 **Detection and quantification of SARS-CoV-2 RNA in plasma:** RNA was extracted from
216 100 µl of plasma using an automated system, eMAG® from bioMérieux® (Marcy l'Etoile,
217 France). Detection and quantification of SARS-CoV-2 RNA was performed in five µl of
218 the eluted solution using the Bio-Rad SARS-CoV-2 ddPCR kit according to
219 manufacturer's specifications on a QX-200 droplet digital PCR platform from the same
220 provider. This PCR targets the N1 and N2 regions of the viral nucleoprotein gene and also
221 the human ribonuclease (RNase) P gene using the primers and probes sets detailed in the
222 CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel [22].
223 Samples were considered positive for SARS-CoV-2 when N1 and/or N2 presented values
224 ≥ 0.1 copies/µL in a given reaction. RNase P gene was considered positive when it
225 presented values ≥ 0.2 copies/µL, following manufacturer`s indications. The test was only
226 considered valid when RNase P gene was positive. Final results were given in copies of
227 cDNA / mL of plasma. IgG specific for the Nucleocapsid Protein of SARS–CoV-2 was
228 detected in 150 µl of plasma using the Abbott Architect SARS-CoV-2 IgG Assay (Illinois,
229 U.S.A). Viral RNA and SARS-CoV-2 IgG were profiled in the same plasma sample.

230 **Statistical analysis:** For the demographic and clinical characteristics of the patients, the
231 differences between groups were assessed using the Chi-square test / Fisher's Exact Test
232 where appropriated for categorical variables. Differences for continuous variables were
233 assessed by using the Kruskal-Wallis test with post hoc tests adjusting for multiple

234 comparisons. Multivariate logistic regression analysis was employed to evaluate the
235 association between viral RNAemia and viral RNA load in plasma with severity, in the
236 comparisons [outpatients vs ward patients] and [ward patients vs ICU patients]. Variables
237 showing significant differences between groups in each comparison in the Kruskal-Wallis
238 test were further introduced in the multivariate analysis as adjusting variables. The list of
239 variables considered as potential adjusting variables were [Age (years)], [Sex (male)],
240 [Alcoholism], [Smoker], [Drug abuse], [Cardiac disease], [Chronic vascular disease],
241 [COPD], [Asthma], [Obesity], [Hypertension], [Dyslipidemia], [Chronic renal disease],
242 [Chronic hepatic disease], [Neurological disease], [HIV], [Autoimmune disease], [Chronic
243 inflammatory bowel disease], [Type 1 diabetes], [Type 2 diabetes], [Cancer], [Invasive
244 mechanical ventilation], [Non-invasive mechanical ventilation], [SARS-CoV-2 IgG],
245 [Temperature (ºC)], [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Bilateral
246 pulmonary infiltrate], [Glucose (mg/dl)], [Creatinine (mg/dl)], [Na (mEq/L)], [K
247 (mEq/L)], [Platelets (cell x 10^3 / µl)], [INR], [D Dimer (pg/ml)], [LDH (UI/L)], [GPT
248 (UI/L)], [Ferritin (pg/ml)], [CRP (mg/dl)], [Haematocrit (%)], [Lymphocytes (cells/mm3)],
249 [Neutrophils (cells/mm3)], [Monocytes (cells/mm3)]. Multivariate logistic regression
250 analysis was performed using the "Enter" method, but also the backward stepwise
251 selection method (Likelihood Ratio) was employed in each case to confirm the association
252 between viral RNAemia and viral RNA load in plasma with disease severity (pin < 0.05,
253 pout < 0.10), not forcing entry of these variables in the model. Correlation analysis were
254 performed using the Spearman test applying the Bonferroni correction of the *p* value.
255 Variables evaluated for correlation with viral RNA load were: [Temperature (ºC)],
256 [Systolic Pressure (mmHg)], [Oxygen saturation (%)], [Lymphocytes (cells/mm3)],
257 [Neutrophils (cells/mm3)], [Monocytes (cells/mm3)], [Creatinine (mg/dl)], [LDH (UI/L)],
258 [GPT (UI/L)], [Platelets (cell x 10^3 / µl)], [INR], [CRP (mg/dl)], and all the biomarkers

259 analyzed by Ella- SimplePlex. Statistical analysis was performed with IBM SPSS® version
260 20 (IBM, Armonk, New York, USA).

261 **Results**

262 **Clinical characteristics of the patients** (Table 1): Patients requiring hospitalization
263 (either general ward or ICU) were older than those patients discharged to their home from
264 the ER. Critically ill patients were more frequently male than those in the other groups.
265 Comorbidities of obesity, hypertension, dyslipidemia and type 2 diabetes were more
266 commonly found in patients requiring hospitalization, with no significant differences found
267 in the comorbidities profile between critically ill and non-critically ill hospitalized patients.
268 14% of the patients in clinical wards required non-invasive mechanical ventilation, while
269 96% of the patients admitted to the ICU required invasive mechanical ventilation.
270 Critically ill patients had increased glucose levels, along with higher concentration of
271 neutrophils in blood, increased levels of ferritin and C-reactive protein (denoting activation
272 of the systemic inflammatory response). Increased levels of INR and D-dimers (reflecting
273 activation of the coagulation system), as well as LDH and GPT, which levels raise as
274 consequence of tissue and liver damage, were also observed in critically ill patients.
275 Patients admitted to the ICU also showed a lower haematocrit, pronounced lymphopenia
276 and lower monocyte counts at admission. ICU patients stayed longer in the hospital than
277 ward patients, with 49 % having a fatal outcome.

278 **Viral RNAemia, viral RNA load in plasma and specific SARS-Cov-2 IgG in the three**
279 **groups of patients.** As depicted in table 1, the frequency of the detection of SARS-CoV-2
280 viral RNA (RNAemia) was significantly higher in the critically ill patients (78%)
281 compared to ward patients (27%) and outpatients (2%) ($p<0.001$). Similarly, the group of
282 critically patients showed higher viral RNA loads in plasma than either ward or outpatients
283 ($p<0.001$) (Table 1 and Figure 1). Non survivors showed the highest concentrations of viral

284 RNA in plasma: viral RNA load (N1 region) in ICU non survivors: 1587 copies / ml
285 [10248]; viral RNA load (N1 region) in ICU survivors 574 copies / mL [1872] (results
286 expressed as median [interquartile rank]); viral RNA load (N2 region) in ICU non
287 survivors: 2798 copies / ml [12012]; viral RNA load (N2 region) in ICU survivors 523
288 copies / mL [1478]. Patients admitted to the wards showed a significant higher frequency
289 of viral RNAemia than outpatients, but viral RNA loads were not significantly different
290 with the latter group (Table 1 and Figure 1). Critically ill patients also had a higher
291 frequency of specific SARS-CoV-2 IgG responses than the other groups (70% in ICU
292 compared to 52% and 49% in the outpatients and ward groups, $p < 0.05$, table 1). No
293 significant differences were found between the group of outpatients and those admitted to
294 the ward. The prevalence of viral RNAemia did not differ between those patients testing
295 positive and those testing negative for SARS-CoV-2 IgG (43.8 % and 40.4 % respectively,
296 p =0.586), who in addition showed no differences in viral RNA load (data not shown).
297 Patients with viral RNAemia showed no differences in the days since onset of symptoms
298 compared to those with no viral RNAemia (8.0 days [6.0]; 8.0 days [7.2], $p = 0.965$). In
299 contrast, samples from patients with SARS-CoV-2 IgG were collected later since disease
300 onset that those without SARS-CoV-2 IgG (10.0 days [7]; 7.0 days [6.0], $p = 0.003$)

301 **Multivariate analysis to evaluate the association between viral RNAemia and viral**
302 **RNA load in plasma with moderate disease and critical illness.** While the proportion of
303 patients with viral RNAemia was higher in the wards group compared to the outpatients'
304 group (table 1), the multivariate analysis did not show a significant association between the
305 presence of viral RNAemia and being hospitalised at the ward, with none of the both
306 methods employed (Additional files 2 and 3). In contrast, when the ward group was
307 compared with critically ill patients, a significant direct association was found between

308 viral RNAemia and viral RNA load in critically ill patients, using the "Enter" method
309 (Table 2) but also the backward stepwise selection method (additional file 4).

310 **Correlations between viral RNA load in plasma and biological responses to SARS-**
311 **CoV-2 infection:** viral RNA load in plasma (targeting either the N1 and the N2 regions)
312 showed the strongest direct correlations with plasma levels of CXCL10, LDH, IL-10, IL-6,
313 IL-15, myeloperoxidase and CCL-2 (MCP-1) and inverse correlations with lymphocytes,
314 monocytes and O2 saturation (Figure 2). These were the parameters whose levels varied
315 the most in critically patients compared with ward and outpatient groups (Figures 3 and 4
316 and additional file 5). CXCL10 was the most accurate identifier of viral RNAemia in
317 plasma (area under the curve (AUC), [CI95%], p) = 0.85 [0.80 – 0.89), <0.001), and IL-15
318 was the cytokine which most accurately differentiated clinical ward patients from ICU
319 patients (AUC: 0.82 [0.76 – 0.88], <0.001). Plasma viral RNA load also showed significant
320 direct correlations with levels of VCAM-1, PDL-1, GM-CSF, G-CSF, neutrophil counts,
321 IL-1ra, CRP, INR, D-dimer, TFNα, Angiopoietin-2, GPT, ICAM-1, IL-7 and Ferritin
322 (Figure 2), with most of these mediators showing the highest variations in the critically ill
323 patients (Figures 3 and 4 and additional file 5).

324 **Discussion**

325 Our study demonstrates that the presence of SARS-CoV-2-RNA in plasma is associated to
326 critical illness in COVID-19 patients, with the strength of association being the highest in
327 those patients with the highest viral RNA loads. This association was independent of other
328 factors also related to disease severity. Moreover, those critically ill patients who died
329 presented with higher viral RNA loads in plasma than those who survived. SARS-CoV-2
330 viral RNA was detected in the plasma of the vast majority of those COVID-19 patients
331 admitted to the ICU (78%). As far as we know, our study is the largest one to date using
332 ddPCR to quantify SARS-CoV-2 RNA load in plasma from COVID-19 patients, and the

333 only one with a multicentric design. Our results are in consonance with those from Veyer
334 *et al*, who, in a pilot study using this technology, found higher viral RNA loads and a
335 prevalence of RNA viremia of 88% in twenty six COVID-19 patients who were critically
336 ill [16]. The results are also in agreement with those of Hagman et al, who, using standard
337 RT-PCR technology, found that the presence of SARS-CoV-2 RNA in serum at hospital
338 admission was associated with a seven-fold increased risk of critical disease and an eight-
339 fold increased risk of death in a cohort of 167 patients hospitalised for COVID-19 [23].

340 Although our study did not determine if the presence of viral RNA in plasma reflects the
341 presence of live virus in peripheral blood, the association found between the presence and
342 concentration of viral RNA in plasma and critical illness suggests that viral replication is
343 more robust in severe COVID-19, and/or that critically ill patients with this disease are not
344 able to control viral replication. This notion is further supported by the correlations found
345 in our study between viral RNA load in plasma and hypercytokinemia involving CXCL10,
346 IL-10, CCL2, IL-6 and IL-15, where the levels of these cytokines were the highest in
347 patients with critical illness. The correlation between viral RNA load and higher levels of
348 cytokines has also been described in the severe infections caused by H5N1 and pandemic
349 H1N1 influenza strains [24] [25]. Active viral replication stimulates the secretion of
350 cytokines by the recognition of viral RNA by endosomal receptors such as toll like
351 receptor 7 (TLR7) in human plasmacytoid dendritic cells and B cells, or TLR8 in myeloid
352 cells [26]. While the elevation of CXCL10, IL-10, CCL2, IL-6 has been extensively
353 documented in severe COVID-19 [9] [10], our work demonstrates a clear correlation
354 between these cytokines and plasma viral load. Furthermore, we report for the first time a
355 major role of IL-15 in severe COVID-19. High levels of IL-15 in critically ill patients with
356 high SARS-CoV-2 RNA load in plasma could be an attempt to stimulate Natural Killer
357 cells to fight the virus [27]. We previously demonstrated that high levels of IL-15, along

358 with IL-6, constituted a signature of critical illness in H1N1 pandemic influenza infection
359 [20].

360 Viral RNA load correlated with higher levels of myeloperoxidase in plasma, which were
361 the highest in those patients admitted to the ICU. This is a marker of neutrophil
362 degranulation and a potent tissue damage factor which has been proposed to play a role in
363 the pathogenesis of ARDS secondary to influenza, by mediating claudin alteration on
364 endothelial tight junctions, eventually leading to protein leakage and viral spread [28]. In
365 this regard, the correlation found between viral RNA load in plasma and higher levels of
366 LDH and GPT could suggest a direct or indirect role of viral replication in mediating tissue
367 destruction in COVID-19.

368 Interesting, but less robust, direct correlations were found between viral RNA load in
369 plasma with GM-CSF and neutrophil counts in blood, further reinforcing the role of
370 neutrophil mediated responses in the pathogenesis of severe COVID-19. The direct
371 correlation with soluble PDL-1 is also relevant, since this the ligand of the inhibitory
372 co-receptor PD1 on T cells, which activation induces anergy of T lymphocytes [29]. This
373 finding reinforces the potential role of immune checkpoint inhibitors in severe COVID-19
374 [30]. In turn, the association found between viral RNA load in plasma and three mediators
375 of endothelial dysfunction (VCAM-1, angiopoietin 2 and ICAM-1), and with coagulation
376 activation markers (D-dimers and INR prolongation) suggests a potential virally linked
377 mechanism in the pathogenesis of endothelitis and thrombosis in COVID-19 disease [7].
378 Finally, the correlation with the acute phase reactants CRP and ferritin suggests a
379 connection between shedding of genomic material of the virus to the blood and the
380 induction of a systemic inflammatory response which is observed in those patients needing
381 critical care.

The strongest inverse correlations found in our study was between SARS-CoV-2 RNA load in plasma and lymphocyte and monocyte counts in peripheral blood, for which critically ill patients showed the lowest values. Active viral replication could be a precipitating event in the pathogenesis of lymphopenia and monocytopenia in severe COVID-19 patients [11] [31], by mediating direct cytopathic actions or stimulating the migration of these cells to the extravascular space to reach the infected tissues [32].

A limitation of our work is its observational nature, which precludes to infer causality. Nonetheless, the observed associations could serve as hypothesis generators, leading to the development of animal models to confirm the potential link between SARS-CoV-2 replication and the dysregulated host responses observed in severe COVID-19.

Conclusion:

Presence of SARS-CoV-2 RNA in plasma is associated with critical illness in patients with COVID-19. The strength of this association increases with viral RNA load in plasma, which in turn correlates with key signatures of dysregulated host response in COVID-19 (figure 5). Our findings suggest a major role of uncontrolled viral replication in the pathogenesis of this disease. Assessment of viral RNAemia and viral RNA load in plasma could be useful to early detect those patients at risk of clinical deterioration, to assess response to treatment and to predict disease outcome.

List of abbreviations

SARS-CoV-2: Severe acute Respiratory Syndrom-Coronavirus-2

LDH: Lactate dehydrogenase

G-CSF: Granulocyte colony-stimulating factor

TLR: toll like receptor

Declarations

Ethics approval and consent to participate: The study was approved by the Committee for Ethical Research of the coordinating institution, "Comite de Etica de la Investigacion con Medicamentos del Area de Salud de Salamanca", code PI 2020 03 452. Informed consent was obtained orally when clinically possible. In the remaining cases, the informed consent waiver was authorized by the Ethics committee.

Consent for publication: not applicable

Availability of data and materials: the datasets generated and/or analysed during the current study are not publicly available since they are still under elaboration for publication by the authors but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by awards from the Canadian Institutes of Health Research, the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative (CIHR OV2 – 170357), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), Dalhousie Medical Research Foundation (DJK), the "Subvenciones de concesión directa para proyectos y programas de investigación del virus SARS-CoV2, causante del COVID-19", FONDO - COVID19, Instituto de Salud Carlos III (COV20/00110, CIBERES, 06/06/0028), (AT) and finally by the "Convocatoria extraordinaria y urgente de la Gerencia Regional de Salud de Castilla y León, para la financiación de proyectos de investigación en enfermedad COVID-19" (GRS COVID 53/A/20) (CA). DJK is a recipient of the Canada Research Chair in Translational

Vaccinology and Inflammation. APT was funded by the Sara Borrell Research Grant CD018/0123 funded by Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (A Way to Achieve Europe programme). The funding sources did not play any role neither in the design of the study and collection, not in the analysis, in the interpretation of data or in writing the manuscript.

Authors 'contribution: JFBM, DJK, JB, RF, FB, AT and RM designed the study. JFBM and DJK wrote the manuscript and interpreted the data. RA coordinated the clinical study and drafted the figures. MGR, DM, PR, FPG, LT, RLI, EB, CA, JMG, JR, RM, MIF, GM, MGE, DC, FDC, JFR, WT, PGJ, GR, IM, EG,IM, SP, SM, PGO, JAC, TRA, CP, JAB, GR, RH, JB, PE, RC, JA, JGB, NM, NBL, LJV, BFC, MAM recruited the patients and /or collected the clinical data. MDG, AO, RO, LMR and JME performed the assays for the detection of SARS-CoV-2 IgG and viremia. APT, CD and AO developed the ddPCR works; CD and NJ profiled the immunological mediators. SR, AMF and MMF developed the statistical analysis and drafted the figures. AAK, ATO, AM and LF performed the literature search. All authors read and approved the final manuscript.

Ackowledgements: we thank SEIMC-GESIDA Foundation for the scientific sponsoring of this project. We thank also the "Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León", which provided the plasma simples used in the healthy control group.

References:

1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. Available from: https://coronavirus.jhu.edu/map.html

2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;

3. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clinical Microbiology and Infection. Elsevier; 2020;26:842–7.

4. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging Microbes & Infections. Taylor & Francis; 2020;9:386–9.

5. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin Infect Dis [Internet]. [cited 2020 Jul 6]; Available from: https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa449/5821311

6. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369:m1443.

7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–8.

8. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–20.

9. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. The Lancet Respiratory Medicine [Internet]. Elsevier; 2020 [cited 2020 Oct 21];0. Available from: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30404-5/abstract

10. Laing AG, Lorenc A, Del Molino Del Barrio I, Das A, Fish M, Monin L, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;

11. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta. 2020;509:180–94.

12. Hupf J, Mustroph J, Hanses F, Evert K, Maier LS, Jungbauer CG. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit Care. 2020;24:527.

488 13. McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune
489 mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet
490 Rheumatol. 2020;2:e437–45.

491 14. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19:
492 immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther.
493 2020;5:128.

494 15. Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, et al. High
495 Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease. Clin
496 Infect Dis. 2020;

497 16. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, et al. Highly sensitive
498 quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value.
499 Clin Infect Dis. 2020;

500 17. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of
501 COVID-19: Current State of the Science. Immunity. 2020;52:910–41.

502 18. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al.
503 Interferon-mediated immunopathological events are associated with atypical innate and
504 adaptive immune responses in patients with severe acute respiratory syndrome. J Virol.
505 2007;81:8692–706.

506 19. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human
507 immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res.
508 2008;133:13–9.

509 20. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramírez
510 P, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe
511 pandemic influenza. Crit Care. 2009;13:R201.

512 21. Rubio I, Osuchowski MF, Shankar-Hari M, Skirecki T, Winkler MS, Lachmann G,
513 et al. Current gaps in sepsis immunology: new opportunities for translational research.
514 Lancet Infect Dis. 2019;19:e422–36.

515 22. CDC. Information for Laboratories about Coronavirus (COVID-19) [Internet].
516 Centers for Disease Control and Prevention. 2020 [cited 2020 Oct 14]. Available from:
517 https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html

518 23. Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, et
519 al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a
520 retrospective cohort study. Clin Infect Dis. 2020;

521 24. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJD, Chau TNB, et al.
522 Fatal outcome of human influenza A (H5N1) is associated with high viral load and
523 hypercytokinemia. Nat Med. 2006;12:1203–7.

524 25. Almansa R, Anton A, Ramirez P, Martin-Loeches I, Banner D, Pumarola T, et al.
525 Direct association between pharyngeal viral secretion and host cytokine response in
526 severe pandemic influenza. BMC Infect Dis. 2011;11:232.

26. Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19: a clue from innate immunity. Immunol Res. 2020;68:161–8.

27. Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 2012;14:247–61.

28. Sugamata R, Dobashi H, Nagao T, Yamamoto K-I, Nakajima N, Sato Y, et al. Contribution of neutrophil-derived myeloperoxidase in the early phase of fulminant acute respiratory distress syndrome induced by influenza virus infection. Microbiol Immunol. 2012;56:171–82.

29. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14:121–37.

30. Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respir Med. 2020;

31. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Torres A. Lymphopenic community acquired pneumonia as signature of severe COVID-19. Journal of Infection. 2020;

32. Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients. Intensive Care Med. 2020;46:1764–5.

Conflicts of interests: the authors declare no conflicts of interests regarding this submission

		Outpatients (1)	Ward (2)	ICU (3)	*p* value (1 vs 2)	*p* value (1 vs 3)	*p* value (2 vs 3)
Characteristics	**Age [years, median (IQR)]**	48.50 [19]	64 [20]	66 [19]	< 0.001	< 0.001	n.s.
	Male [%, (n)]	46 (23)	50 (50)	64 (64)	n.s.	0.035	0.046
Comorbidities, [% (n)]	**Alcoholism**	2 (1)	0 (0)	1 (1)	n.s.	n.s.	n.s.
	Smoking	4 (2)	5 (5)	6 (6)	n.s.	n.s.	n.s.
	Drug abuse	2 (1)	0 (0)	0 (0)	n.s.	n.s.	n.a.
	Cardiac disease	4 (2)	13 (13)	9 (9)	n.s.	n.s.	n.s.
	Chronic vascular disease	2 (1)	2 (2)	5 (5)	n.s.	n.s.	n.s.
	COPD	2 (1)	2 (2)	3 (3)	n.s.	n.s.	n.s.
	Asthma	8 (4)	6 (6)	2 (2)	n.s.	n.s.	n.s.
	Obesity	4 (2)	26 (26)	26 (26)	0.001	0.001	n.s.
	Hypertension	24 (12)	44 (44)	45 (45)	0.017	0.012	n.s.
	Dyslipidemia	16 (8)	41 (41)	34 (34)	0.002	0.021	n.s.
	Chronic renal disease	2 (1)	3 (3)	3 (3)	n.s.	n.s.	n.s.
	Chronic hepatic disease	2 (1)	0 (0)	3 (3)	n.s.	n.s.	n.s.
	Neurological disease	0 (0)	6 (6)	3 (3)	n.s.	n.s.	n.s.
	HIV	0 (0)	0 (0)	1 (1)	n.a.	n.s.	n.s.
	Autoimmune disease	2 (1)	1 (1)	1 (1)	n.s.	n.s.	n.s.
	Chronic inflammatory bowel disease	0 (0)	2 (2)	1 (1)	n.s.	n.s.	n.s.
	Type 1 diabetes	0 (0)	0 (0)	3 (3)	n.a.	n.s.	n.s.
	Type 2 diabetes	0 (0)	23 (23)	22 (22)	< 0.001	< 0.001	n.s.
	Cancer	6 (3)	2 (2)	1 (1)	n.s.	n.s.	n.s.
Treatment during hospitalization, [% (n)]	**Invasive mechanical ventilation**	0 (0)	0 (0)	96 (96)	n.a.	< 0.001	< 0.001
	Non-invasive mechanical ventilation	0 (0)	14 (14)	34 (34)	0.004	< 0.001	0.002
	Hydroxychloroquine	77.6 (38)	89 (89)	99 (99)	n.s.	< 0.001	0.003
	Chloroquine	4.1 (2)	7 (7)	0 (0)	n.s.	0.042	0.007
	Corticoids	6.7 (3)	29 (29)	85 (85)	0.002	< 0.001	< 0.001
	Azithromycin	15.9 (7)	84 (84)	84 (84)	< 0.001	< 0.001	n.s.
	Remdesivir	0 (0)	1 (1)	9 (9)	n.s.	0.029	0.009
	Tocilizumab	0 (0)	13 (13)	33 (33)	0.008	< 0.001	0.001
	Lopinavir/ritonavir	74 (37)	35 (35)	96 (96)	< 0.001	< 0.001	< 0.001
	Beta Interferon	0 (0)	0 (0)	55 (55)	n.a.	< 0.001	< 0.001
Time course and outcome	**Hospital stay [days, median, (IQR)]**	-	9 (6)	24 (19)	n.a.	n.a.	< 0.001
	Viral RNAemia [% (n)]	2 (1)	27 (27)	78 (78)	< 0.001	< 0.001	< 0.001
	Viral RNA load in plasma (N1) (copies / mL, median, (IQR))	0 (0)	0 (91)	829 (4444)	n.s.	< 0.001	< 0.001
	Viral RNA load in plasma (N2) (copies / mL, median, (IQR))	0 (0)	0 (93)	836 (4939)	n.s.	< 0.001	< 0.001
	SARS-CoV-2 IgG, [% (n)]	52 (26)	49 (49)	70 (70)	n.s.	0.030	0.002
	Hospital mortality, [% (n)]	0 (0)	0 (0)	49(49)	n.a.	< 0.001	< 0.001
	Temperature (ºC) [median (IQR)]	36.50 (1.0)	36.80 (1.4)	37.00 (1.4)	-	-	-
	Systolic Pressure (mmHg) [median (IQR)]	120 (29)	126 (25)	120 (26)	n.s.	n.s.	0.001
	Oxygen saturation (%) [median (IQR)]	96 (3)	94 (5)	92 (6)	0.002	< 0.001	0.002

Measurements at diagnosis	**Pulmonary infiltrate [% (n)]**	72 (36)	93 (93)	100 (100)	< 0.001	< 0.001	0.007
	Bilateral pulmonary infiltrate [% (n)]	26 (13)	67 (67)	93 (93)	< 0.001	< 0.001	< 0.001
	Glucose (mg/dl) [median (IQR)]	99.5 (22)	112 (31)	160.50 (83)	< 0.001	< 0.001	< 0.001
	Creatinine (mg/dl) [median (IQR)]	0.84 (0.18)	0.91 (0.33)	0.88 (0.57)	-	-	-
	Na (mEq/L) [median (IQR)]	138 (4)	138 (5)	138.50 (7)	-	-	-
	K (mEq/L) [median (IQR)]	3.90 (0.50)	4.10 (0.68)	3.95 (0.90)	-	-	-
	Platelets (cell x 10^3 / µl) [median (IQR)]	223 [97]	207 [113]	204 [126]	-	-	-
	INR [median (IQR)]	1.04 (0.10)	1.11 (0.13)	1.22 (0.22)	0.004	< 0.001	< 0.001
	D Dimer (pg/ml) [median (IQR)]	795278 [828234]	1597362 [2024704]	6182104 [52690922]	< 0.001	< 0.001	< 0.001
	LDH (UI/L) [median (IQR)]	214 (73)	278 (138)	496 (285)	0.002	< 0.001	< 0.001
	GPT (UI/L) [median (IQR)]	27 (43)	29 (29)	44 (44.50)	n.s.	0.021	0.001
	Ferritin (pg/ml) [median (IQR)]	359507 [458748]	523805 [534757]	923687 [1526492]	n.s.	< 0.001	0.002
	CRP (mg/dl) [median (IQR)]	1.40 (3.50)	40.90 (89.18)	91 (182.10)	< 0.001	< 0.001	0.031
Measurements at diagnosis	**Haematocrit (%) [median (IQR)]**	43.15 (4.72)	42.50 (6.50)	38.15 (6.48)	n.s.	< 0.001	< 0.001
	WBC (cells/mm3) [median (IQR)]	6450 (2815)	7005 (4115)	9145 (6613)	n.s.	< 0.001	0.006
	Lymphocytes (cells/mm3) [median (IQR)]	1400 (805)	1000 (433)	540 (445)	0.006	< 0.001	< 0.001
	Neutrophils (cells/mm3) [median (IQR)]	4260 (2625)	5250 (3918)	8300 (5880)	n.s	< 0.001	< 0.001
	Monocytes (cells/mm3) [median (IQR)]	500 (300)	400 (300)	300 (280)	n.s.	< 0.001	< 0.001

Table 1: Clinical characteristics of the patients: continuous variables are represented as [median, (interquartile range, IQR)]; categorical variables are represented as [%, (n)].; INR, International Normalized Ratio; n.s., not significant; n.a., not applicable. COPD (Chronic obstructive pulmonary disease), HIV (Human Immunodeficiency Virus), INR (International Normalized Ratio), LDH (Lactic Acid Dehydrogenase), GPT (glutamic-pyruvate transaminase); CRP (C-reactive protein), WBC (white blood cell).

	OR [CI95%]	*p*	OR [CI95%]	*p*	OR [CI95%]	*p*
Sex (male)	2.055 [0.656 - 6.432	0.216	1.647 [0.508 - 5.337]	0.406	1.608 [0.500 - 5.166]	0.425
Systolic Pressure (mmHg)	0.985 [0.960 - 1.011	0.253	0.984 [0.958 - 1.011]	0.247	0.984 [0.957 - 1.012]	0.261
O2 Saturation (%)	1.069 [0.986 - 1.160]	0.107	1.076 [0.992 - 1.167]	0.079	1.082 [0.993 - 1.180]	0.071
Bilateral pulmonary infiltrate	2.343 [0.469 - 11.707]	0.300	3.088 [0.566 - 16.852]	0.193	3.064 [0.539 - 17.430]	0.207
Glucose (mg/dl)	1.008 [1.001 - 1.015]	0.028	1.007 [1.000 - 1.015]	0.061	1.007 [0.999 - 1.014]	0.070
INR	1.123 [0.433 - 2.915]	0.812	1.245 [0.469 - 3.305]	0.661	1.377 [0.519 - 3.657]	0.521
D-dimer (pg/mL)	1.000 [1.000 - 1.000]	0.294	1.000 [1.000 - 1.000]	0.190	1.000 [1.000 - 1.000]	0.420
LDH (UI/L)	1.009 [1.004 - 1.014]	0.000	1.008 [1.003 - 1.013]	0.002	1.009 [1.004 - 1.014]	0.001
GPT (UI/L)	1.005 [0.992 - 1.019]	0.443	1.005 [0.991 - 1.019]	0.516	1.006 [0.992 - 1.021]	0.402
Ferritin (pg/mL)	1.000 [1.000 - 1.000]	0.705	1.000 [1.000 - 1.000]	0.856	1.000 [1.000 - 1.000]	0.835
CRP (mg/dl)	0.998 [0.992 - 1.003]	0.420	0.999 [0.993 - 1.005]	0.749	0.998 [0.993 - 1.004]	0.547
Haematocrit (%)	0.770 [0.676 - 0.877]	0.000	0.762 [0.665 - 0.872]	0.000	0.737 [0.633 - 0.858]	0.000
SARS-CoV-2 IgG (Yes)	1.967 [0.627 -6.170]	0.246	1.835 [0.562 - 5.987]	0.315	1.918 [0.577 - 6.377]	0.288
Lymphocytes (cells/mm3)	0.998 [0.996 - 1.000]	0.011	0.998 [0.996 - 1.000]	0.012	0.998 [0.996 - 0.999]	0.010
Monocytes (cells/mm3)	0.998 [0.995 - 1.001]	0.180	0.998 [0.995 - 1.001]	0.212	0.999 [0.996 - 1.002]	0.463
Neutrophils (cells/mm3)	1.000 [1.000 - 1.000]	0.262	1.000 [1.000 - 1.000]	0.326	1.000 [1.000 - 1.000]	0.239
Viral RNAemia (Yes)	**3.916 [1.183 - 12.968]**	**0.025**	**-**	**-**	**-**	**-**
Viral RNA load (N1) in plasma, log (copies/mL)	**-**	**-**	**1.962 [1.244 - 3.096]**	**0.004**	**-**	**-**
Viral RNA load (N2) in plasma, log (copies/mL)	**-**	**-**	**-**	**-**	**2.229 [1.382 - 3.595]**	**0.001**

Table 2: Multivariate logistic regression analysis comparing wards patients against critically ill patients (Enter method). The association between viral RNAemia or viral RNA load targeting the N1 region, or viral RNA load targeting the N2 region with critical illness was evaluated adjusting by major confounding factors.



Figure 1: Viral RNA load in plasma, targeting the N1 region (left) and the N2 region (right), in the three groups of patients. Results are provided as copies of cDNA per mL of plasma.

	Correlation coefficients ($p < 0.0012$)		-0.44 0.60
Mediator	**VIRAL RNA LOAD (N1) (copies/mL)**	**VIRAL RNA LOAD (N2) (copies/mL)**	**Biological implications**
CXCL10			Chemotaxis of T cells
LDH (UI/L)			Tissue damage
IL-10 (pg/mL)			Immunosupression / immunomodulation
IL-6 (pg/mL)			Inflammation / Induction of Th17 adaptive immunity
IL-15 (pg/mL)			NK cell activation
Myeloperoxidase (pg/mL)			Neutrophil degranulation
CCL-2 (MCP-1) (pg/mL)			Chemotaxis of monocytes
VCAM-1 (pg/mL)			Endothelial dysfunction
PDL-1 (pg/mL)			Immunosupression / immunomodulation
GM-CSF (pg/mL)			Neutrophils and monocytes mobilization and activation
G-CSF (pg/mL)			Neutrophils mobilization and activation
Neutrophils (cells/mm3)			Innate immunity enhancement
IL-1ra (pg/mL)			Immunosupression / immunomodulation
CRP (mg/dl)			Inflammation (acute phase reactant)
INR			Coagulation activation
DDIMER (pg/mL)			Coagulation activation
TFNα (pg/mL)			Inflammation - induction of Th1 adaptive immunity
Angiopoietin-2			Endothelial dysfunction
GPT (UI/L)			Liver damage
ICAM-1 (pg/mL)			Endothelial dysfunction
IL-7 (pg/mL)			Lymphopoiesis and lymphocyte survival
Ferritin (pg/mL)			Inflammation (acute phase reactant)
Oxygen saturation (%)			Respiratory failure
Monocytes (cells/mm3)			Defective antigen presentation / phagocytosis
Lymphocytes (cells/mm3)			Adaptive immunity dysfunction

Figure 2. Heat map representing the Spearman correlation coefficients between viral RNA load in plasma targeting the N1 and the N2 regions and representative indicators of host dysregulated response.



Figure 3. Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy control and the bars significant differences between the other groups.



Figure 4: Levels of laboratory parameters indicating host dysregulated response across groups. † indicates significant difference with the healthy control and the bars significant differences between the other groups.



Figure 5: Integrative model depicting the correlations found between the indicators of host dysregulated responses and SARS-CoV-2 RNA load in plasma.

Hospital	Outpatients	Wards	ICU
Hospital Clínico Universitario de Valladolid	0	0	45
Hospital General Universitario Gregorio Marañón (Madrid)	44	4	25
Hospital Universitario Infanta Leonor (Madrid)	0	30	0
Hospital Universitario y Politécnico de La Fe (Valencia)	0	27	0
Hospital Universitario Rio Hortega (Valladolid)	2	22	23
Hospital Universitario Príncipe de Asturias (Madrid)	4	17	1
Hospital Universitario de Burgos	0	0	2
Hospital Universitario de León	0	0	4
Total	50	100	100

Additional file 1: recruited patients in each hospital

	OR [CI 95%]	*p*
Age (years)	1.071 [1.024 - 1.121]	0.003
Obesity	5.618 [0.841 - 37.552]	0.075
Hypertension	1.024 [0.279 - 3.756]	0.972
Dyslipidemia	1.521 [0.354 - 6.532]	0.573
O2 saturation	1.077 [0.946 - 1.226]	0.261
Bilateral infiltrate	7.652 [2.050 - 28.558]	0.002
Glucose (mg/dl)	1.022 [0.992 - 1.054]	0.156
INR	3.346 [0.121 - 92.829]	0.476
D Dimer (pg/ml)	1.000 [1.000 - 1.000]	0.111
LDH (UI/L)	1.005 [0.998 - 1.012]	0.176
CRP (mg/dl)	1.032 [1.012 - 1.052]	0.002
Lymphocytes (cells/mm3)	1.000 [0.998 - 1.001]	0.440
Monocytes (cells/mm3)	0.998 [0.996 - 1.001]	0.223
Neutrophils (cells/mm3)	1.000 [1.000 - 1.000]	0.382
Viral RNAemia	3.793 [0.344 - 41.845]	0.277

Additional file 2. Multivariate logistic regression analysis comparing outpatients against wards patients (Enter method). The association between viral RNAemia with hospitalization at the wards was evaluated adjusting by major confounding factors.

	OR [CI95%]	*p*
Age	1.057 [1.017 - 1.098]	0.005
Obesity	6.675 [1.129 - 39.472]	0.036
Bilateral infiltrate	6.400 [2.153 - 19.024]	0.001
Glucose (mg/dl)	1.027 [0.999 - 1.055]	0.058
CRP (mg/dl)	1.032 [1.013 -1.051]	0.001
Monocytes (cells/mm3)	0.997 [0.995 - 1.000]	0.017

Additional file 3. Multivariate logistic regression analysis comparing outpatients against wards patients (backward stepwise selection method / Likelihood Ratio).

The association between viral RNAemia with hospitalization at the wards was evaluated adjusting by major confounding factors, but it was not selected in the final model.

	OR [CI95%]			p	OR [CI95%]			p	OR [CI95%]			p
Systolic Pressure (mmHg)	0.976	0.953	1.000	0.049	0.974	0.949	0.999	0.040	0.974	0.950	0.999	0.042
Glucose (mg/dl)	1.006	1.000	1.012	0.050	1.006	1.000	1.012	0.055	1.005	0.999	1.012	0.088
D-dimer (pg/mL)	1.000	1.000	1.000	0.057	1.000	1.000	1.000	0.025	1.000	1.000	1.000	0.088
LDH (UI/L)	1.008	1.004	1.011	0.000	1.006	1.003	1.010	0.001	1.007	1.004	1.011	0.000
Haematocrit (%)	0.798	0.717	0.888	0.000	0.789	0.706	0.881	0.000	0.775	0.688	0.873	0.000
Lymphocytes (cells/mm3)	0.997	0.996	0.999	0.000	0.997	0.996	0.999	0.000	0.997	0.996	0.999	0.000
Viral RNAemia (Yes)	4.270	1.575	11.580	0.004								
Viral RNA load (N1) in plasma, log (copies/mL)					2.005	1.350	2.978	0.001				
Viral RNA load (N2) in plasma, log (copies/mL)									2.071	1.419	3.022	0.000

Additional file 4. Multivariate logistic regression analysis comparing wards patients against ICU patients (backward stepwise selection method / Likelihood Ratio). The association between viral RNAemia and viral RNA load with critical illness was evaluated adjusting by major confounding factors.

	Healthy Controls (0)	Outpatients (1)	Ward (2)	ICU (3)	*p* (0 vs 1)	*p* (0 vs 2)	*p* (0 vs 3)	*p* (1 vs 2)	*p* (1 vs 3)	*p* (2 vs 3)
ICAM-1 (pg/ml)	289208 [92857]	358431.50 [88702.30]	377655 [150081.80]	466818 [202189.80]	0.036	< 0.001	< 0.001	n.s.	< 0.001	< 0.001
Lipocalin-2 (pg/ml)	82634.50 [29205.30]	73134.50 [32007.30]	94077 [49868]	100165 [57819.80]	n.s.	n.s.	n.s.	0.011	< 0.001	n.s.
Myeloperoxidase (pg/ml)	27541.50 [12906.80]	41902 [30413.80]	88244.50 [78145]	141971.50 [148623.50]	n.s.	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
VCAM-1 (pg/ml)	618380 [195510.50]	800393 [403378]	1191387 [618827]	1248699.50 [603679]	0.021	< 0.001	< 0.001	< 0.001	< 0.001	n.s.
PD-L1 (pg/ml)	55.85 [33.27]	110.50 [120.68]	178 [114.25]	228 [137.75]	0.031	< 0.001	< 0.001	0.045	< 0.001	0.031
G-CSF (pg/ml)	6.90 [7.67]	23.55 [20.48]	31.95 [42.85]	36.25 [53.35]	< 0.001	< 0.001	< 0.001	n.s.	0.022	n.s.
IL-1b (pg/ml)	0.44 [1.65]	0.16 [0.30]	0.44 [0.53]	0.38 [0.51]	n.s.	n.s.	n.s.	0.005	< 0.001	n.s.
IL-10 (pg/ml)	1.59 [0.48]	4.19 [6.68]	9.11 [10.14]	17 [22.25]	0.002	< 0.001	< 0.001	0.007	< 0.001	< 0.001
IL-17A (pg/ml)	1.95 [1.08]	2.38 [1.45]	2.32 [1.44]	3.06 [2.87]	n.s.	0.047	0.002	n.s.	n.s.	n.s.
GM-CSF (pg/ml)	0.66 [0.42]	1.07 [0.54]	1.10 [0.67]	1.62 [1.01]	n.s.	n.s.	< 0.001	n.s.	< 0.001	< 0.001
IL-7 (pg/ml)	1.81 [1.49]	2.04 [3.12]	3.19 [4.19]	4.84 [5.17]	n.s.	0.009	< 0.001	0.017	< 0.001	n.s.
CXCL10 (pg/ml)	91.9 [71.85]	470.50 [731.50]	977.50 [943]	1609.50 [1693.75]	0.003	< 0.001	< 0.001	0.002	< 0.001	0.003
Angiopoietin-2 (pg/ml)	708 [260.75]	809 [479.75]	1128 [779.50]	1769.50 [2064.25]	n.s.	0.001	< 0.001	0.008	< 0.001	0.001
IL-1ra (pg/ml)	478 [1159.75]	653.50 [1039.25]	1796 [1896]	1634 [4472.50]	n.s.	< 0.001	< 0.001	< 0.001	< 0.001	n.s
IL-6 (pg/ml)	1.27 [0.83]	6.34 [12.42]	33.25 [48.10]	105.50 [252.23]	0.027	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
CCL2 (pg/ml)	103.50 [39]	189 [157.50]	283.50 [304]	490 [881.75]	0.012	< 0.001	< 0.001	0.031	< 0.001	< 0.001
IL-12p70 (pg/ml)	0.62 [0.71]	1.46 [0.67]	1.51 [0.71]	1.36 [0.94]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	n.s.
IL-2 (pg/ml)	0.02 [0.09]	0.53 [0.39]	0.49 [0.57]	0.63 [0.83]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	n.s.
IL-4 (pg/ml)	0.13 [0.27]	0.33 [0.34]	0.33 [0.39]	0.29 [0.37]	0.021	0.006	0.041	n.s.	n.s.	n.s.
IL-15 (pg/ml)	2.11 [0.54]	3.85 [3.7]	4.89 [2.90]	8.38 [5.19]	0.001	< 0.001	< 0.001	n.s.	< 0.001	< 0.001
Granzyme-B (pg/ml)	12 [15.75]	33.20 [27.92]	46.15 [40.03]	39.25 [35.58]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	0.036
INFγ (pg/ml)	0.68 [0.45]	4.35 [14.16]	7.42 [15.13]	3.44 [8.50]	< 0.001	< 0.001	< 0.001	n.s.	n.s.	0.021

TNFα (pg/ml)	5.11 [1.79]	10.60 [4.18]	13 [6.46]	12.95 [10.34]	< 0.001	< 0.001	< 0.001	0.021	0.006	n.s.

691

692 **Additional file 5. Laboratory parameters 'levels across groups.**